Structure - Function studies of arginine at position 276 in CTX-M β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 792-797

  Pérez llarena, Francisco José ^a   Cartelle, Mónica ^a   Mallo, Susana ^a   Beceiro, Alejandro ^a   Pérez, Astrid ^a   Villanueva, Rosa ^a   Romero, Antonio ^b   Bonnet, Richard ^c   Bou, Germán ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

lactamase inhibition; Cefotaxime hydrolysis; Clavulanate

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ARGININE; ASPARAGINE; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CLAVULANIC ACID; CYSTEINE; EXTENDED SPECTRUM BETA LACTAMASE; GLYCINE; HISTIDINE; IMIPENEM; NITROCEFIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SERINE; TRYPTOPHAN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME ACTIVE SITE; ENZYME DEGRADATION; ENZYME PURIFICATION; ENZYME STRUCTURE; ESCHERICHIA COLI; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFOTAXIME; CEPHALOTHIN; CHROMATOGRAPHY, AFFINITY; CLAVULANIC ACID; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; INHIBITORY CONCENTRATION 50; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED;

EID: 41149170260     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn031     Document Type: Article

References (23)

1. Bonnet R. Growing group of extended-spectrum β-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
2. Poirel L, Naas T, Le Thomas I et al. CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 2001; 45: 3355-61.
3. Bonnet R, Dutour C, Sampaio JL et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly. Antimicrob Agents Chemother 2001; 8: 2269-75.
4. Bonnet R, Recule C, Baraduc R et al. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 2003; 52: 29-35.
5. Cartelle M, Tomas M, Molina F et al. High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob Agents Chemother 2004; 48: 2308-13.
6. Delmas J, Robin F, Carvalho F et al. Prediction of the evolution of ceftazidime resistance in extended-spectrum β-lactamase CTX-M-9. Antimicrob Agents Chemother 2006; 50: 731-8.
7. Stapleton PD, Shannon KP, French GL. Construction and characterization of mutants of the TEM-1 β-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors. Antimicrob Agents Chemother 1999; 43 1881-7.
8. Randegger CC, Hachler H. Amino acid substitutions causing inhibitor resistance in TEM β-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum β-lactamases. J Antimicrob Chemother 2001; 47: 547-54.
9. Gazouli M, Legakis NJ, Tzouvelekis LS. Effect of substitution of Asn for Arg-276 in the cefotaxime-hydrolyzing class A β-lactamase CTX-M-4. FEMS Microbiol Lett 1998; 169: 289-93.
10. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: Mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 1995; 39: 2593-601.
11. Chen Y, Delmas J, Sirot T et al. Atomic resolution structures of CTX-M β-lactamases: Extended spectrum activities from increased mobility and decreased stability. J Mol Biol 2005; 348: 349-62.
12. Ibuka A, Taguchi A, Ishiguro M et al. Crystal structure of the E166A mutant of extended-spectrum β-lactamase Toho-1 at 1.8 Å resolution. J Mol Biol 1999; 285: 2079-87.
13. Jelsch C, Lenfant F, Masson JM et al. β-Lactamase TEM1 of E. coli crystal structure determination at 2.5 Å resolution. FEBS Lett 1992; 299: 135-42.
14. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
15. Chaibi EB, Sirot D, Paul G et al. Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447-58.
16. Aumeran C, Chanal C, Labia R et al. Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum β-lactamase CTX-M-9. Antimicrob Agents Chemother 2003; 47: 2958-61.
17. Gazouli M, Tzelepi E, Sidorenko SV et al. Sequence of the gene encoding a plasmid-mediated cefotaxime-hydrolyzing class A β-lactamase (CTX-M-4): Involvement of serine 237 in cephalosporin hydrolysis. Antimicrob Agents Chemother 1998; 42: 1259-62.
18. Ho SN, Hunt HD, Horton RM et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-9.
19. Galleni M, Francecchini N, Quinting B et al. Use of the chromosomal class A β-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory β-lactam compounds. Antimicrob Agents Chemother 1994; 38: 1608-14.
20. Sirot D, Recule C, Chaibi EB et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997; 41: 1322-5.
21. Kraulis PJ. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991; 24: 946-50.
22. Merritt EA, Bacon DJ. Raster 3D: Photorealistic molecular graphics. Methods Enzymol 1997; 277: 505-24.
23. Brunger AT, Adams PD, Clore GM et al. Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54: 905-21.